Phone: 027-83692745


Academic Areas:Pharmaceutical Chemistry

Research Interests:Design and synthesis of Antitumor drug , geriatric drug and immunosuppressive drug

Academic Degrees

Master in Organic Chemistry, 1985, Wuhan University, Wuhan, China;

BA in Organic Chemistry, 1982, Wuhan University, Wuhan, China.

Professional Experience

Professor (1999-present); School of Pharmacy, HUST, Wuhan, China

Associate Professor (1994-1999); School of Pharmacy, Tongji Medical University , Whan, China

Lecture (1990-1994); School of Pharmacy, Tongji Medical University , Whan, China

Selected Publications

1. Lin Xie, Feng-Chao Jiang, Li-Min Zhang, Wen-Tao He, Jian-Hua Liu, Ming-Qiang Li, Xue Zhang, Shuai Xing, Hui Guo, Ping Zhou: Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer[J], JNCI J Natl Cancer Inst (2016) 108(4): djv364.(SCI 11.37)

2. Jian-Min Liu,,* Peng-Fei Wu,Jing Rao,Jun Zhou, Zu-Cheng Shen,Han Luo,Jian-Geng Huang,Xiao Liang,Li-Hong Long,Qing-Guo Xie,Feng-Chao Jiang, Fang Wang & Jian-Guo Chen: ST09, a Novel Thioester Derivative of Tacrine, Alleviates Cognitive Deficits and Enhances Glucose Metabolism in Vascular Dementia Rats[J], CNS Neuroscience & Therapeutics 22 (2016) 220–229(SCI 4.019)

3, Li L, Chen M, Jiang FC, Design, synthesis, and evaluation of 2-piperidone derivatives for the inhibition of β-amyloid aggregation and inflammation mediated neurotoxicity[J]. Bioorg. Med chem,24(2016),1853-1865(SCI 2.923)

4. Xue Zhanga, Shuai Xinga, , Mingqiang Li a, Limin Zhanga, Lin Xie , Wentao Hed, Jianhua Liu , Sheng Changa, Fengchao Jiang ,, Ping Zhoua,,Beyond knockout:Anovel homodimerization-targeting MyD88 inhibitor prevents and cures type 1 diabetes in NOD mice[J],Metabolism,metabolism-clinical and experimental 65(2016),1267-1277(Sci 4.375)

5. Li-Min Zhang, Jian-Hua Liu,*, Cheng-Biao Xue,, Ming-Qiang, Shuai Xing,

Xue Zhang, Wen-Tao He, Feng-Chao Jiang, Xia Lu1 & Ping ZhouPharmacological inhibition of MyD88 homodimerization counteracts renal ischemia reperfusion-induced progressive renal injury in vivo and in vitro Scientific Reports | 6:26954 | DOI: 10.1038/srep26954Published: 01 June 2016(SCI 5.228)

6.GUAN Xin-lei1, JIANG Feng-chao*, WANG Yue1, WU Peng-fei, WANG Fang, CHEN Jian-guo;Pharmacophore identification of novel dual-target compounds targeting AChE and PARP-1[J], Acta Pharmaceutica Sinica 2014, 49 (6): 819 −823

7.C. Li, X. Huang, Y. Liu, L. Zhang, M. Li, F. Jiang, W. Huang and P. Zhou, Dendritic Cells Play an Essential Role in Transplantation Responses via Myeloid Differentiation Factor 88 Signaling[J], Transplantation proc. 46, 1842-1846(2013).

8. Yue Wang, Xin-Lei Guan, Peng-Fei Wu,Can-Ming Wang, Hui Cao,Lei Li, Xiao-Juan Guo, Fang Wang, Na Xie, Feng-Chao Jiang and Jian-Guo Chen*,Multifunctional Mercapto-tacrine Derivatives for Treatment of Age-Related Neurodegenerative Diseases[J], Journal of Medicinal Chemistry 55(7), 3588-3592. 2012

9. Yue Wang, Fang Wang, Jun-Ping Yu, Feng-Chao Jiang, Xin-Lei Guan, Can-Ming Wang et al Novel multipotent phenylthiazole–tacrine hybrids for the inhibition of cholinesterase activity, b-amyloid aggregation and Ca2+ overload[J],Bio Med Chem,20 (2012) 6513–6522

10. Wen-Ting Zhang,Feng-Chao Jiang et al, Pharmacopore hypothesis generation of BACE-1 inhibitors and pharmacophore-driven identification of potent multi-target neuroprotective agents[J],Med Chem Res (2012) 21:3656–3668

Conference Report

1、Fengchao Jiang, The design of the innate immunity system regulator and the function of it which acting on the targets of AD pathogeny pathway network,ISBOC-9 & ISCMC-8 ’2012 ,August 25-29, 2012 Beijing P. R. China。IL

2、 Fengchao Jiang,Studies on the Molecular Mechaism of Novel MyD88 Inhibitors,7th-ICNS&I,2014,oct.26-28, 2014,Suzhou P.R.China IL

3. Fengchao Jiang,The design and affect for aggregation of the compounds acting for MyD88, CMCS 2015 & 5th CPA-RSC Symposium on Medicinal Chemistry, August 25-29, 2015 Lanzhou P. R. China。IL

4. fengchao Jiang, The optimizing of Lead compounds acting on MyD88 assisted by molecular docking, 8th-ICMS&I Sep. 24-26,2016, DaLian P. R. China。IL

Working Papers

Books(after 2012)

1、Medicinal Chemistry, ISBN 978-7-308-09469-6,Zhejing university press,2012.6,subeditor,P10-55

2、Drug Design(3th edition),ISBN 978-7-04-042869-8:,Higher Education Press,12th Five-year plan teaching material,participate in writing(Chapter 6,p133-244)

3、Drug Design, ISBN 978-7-5067-7885-5,China Medical Science Press,13th Five-year plan teaching material,,chief editor(Chapter1,6,p1-13;122-146)

4、Inorganic Chemistry (7th edition), ISBN 978-7-117-22035-1/R-23087,People`s Medical publishing House,13th Five-year plan teaching material,chief editor(Chapter 9,p212-281)

5.Inorganic Chemistry leaning guidance and problem sets (4th edition), ISBN 978-7-117-22402-4/R.22403,People`s Medical publishing House,13th Five-year plan teaching material,chief editor

patents(after 2012)

1. Phenylpiperazine derivative for inhibiting tumor metastasis and tumor angiogenesis, ZL 201110146835.4,(authorization,2013-08-21)

2. 2-Aminothiazole derivative, preparation method, and use, ZL 201110049687.4(authorization, 2016.1.13)

3. Pharmaceutical use of aminothiazole MyD88 specificity inhibitor, ZL 201110049579.7 authorization, 2013.6.2);WO/2012/116585

Awards and Honors

Courses Taught

514.504: Drug Design

514.508: Drug Synthesis

514.511: Bio-information

1002141: Protein Structure Modeling and Drug Design

1004371: Drug Design


· 1. Studies on immunosuppressive agent which having novel mechanism (The School funds of HUST, China, 2014-2015).

· 2. The development of novel TLR/MyD88 inhibitor (Huadong Medicine Co. LTD, 2011-2014).

· 3. Studies on the design and the function for AD pathogenic network of the compounds acting on MyD88 Via TLRs signal passageway(NSFC 81673353 2017-2020).

Login and edit information